Patent of Eli-Lilly's Blockbuster Lung Cancer Drug Alimta Upheld

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.

patent

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. for the drugmaker' s blockbuster lung-cancer drug, Alimta.

s,

Teva Pharmaceutical Industries

he '209

Patent

a

The court said the defendantLtd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of tre invalid.

However, the decision that would preserve the $2.6 billion-a-year drug from generic competition until 2022, could change if generic drug companies appeal the ruling.

Read the complete report here:

http://reut.rs/1s2sdUK

Source: Reuters